PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
12372676-5	2002	Zofenoprilat, the active form of zofenopril, significantly and dose dependently reduced the intracellular reactive oxygen species (ROS) and superoxide formation induced by oxidized low-density lipoprotein (ox-LDL) (P <.001) and tumor necrosis factor-alpha (TNF-alpha) (P <.001).	zofenoprilate	0-12	tumor necrosis factor	Homo sapiens	231-258
12372676-7	2002	Zofenoprilat but not enalaprilat also decreased the consumption of the intracellular GSH induced by ox-LDL (P <.01) and TNF-alpha (P <.01).	zofenoprilate	0-12	tumor necrosis factor	Homo sapiens	123-132
12372676-5	2002	Zofenoprilat, the active form of zofenopril, significantly and dose dependently reduced the intracellular reactive oxygen species (ROS) and superoxide formation induced by oxidized low-density lipoprotein (ox-LDL) (P <.001) and tumor necrosis factor-alpha (TNF-alpha) (P <.001).	zofenoprilate	0-12	tumor necrosis factor	Homo sapiens	260-269
11145066-1	2000	Zofenopril is a pro-drug designed to undergo metabolic hydrolysis yielding the active free sulfhydryl compound zofenoprilat, which is an angiotensin converting enzyme (ACE) inhibitor, endowed also with a marked cardioprotective activity.	zofenoprilate	111-123	angiotensin I converting enzyme	Homo sapiens	137-166
12372676-8	2002	Although zofenoprilat significantly and dose dependently reduced the expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), and E-selectin induced by ox-LDL (P <.01) and TNF-alpha (P <.01) on HUVECs, enalaprilat did not.	zofenoprilate	9-21	vascular cell adhesion molecule 1	Homo sapiens	83-116
12372676-8	2002	Although zofenoprilat significantly and dose dependently reduced the expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), and E-selectin induced by ox-LDL (P <.01) and TNF-alpha (P <.01) on HUVECs, enalaprilat did not.	zofenoprilate	9-21	vascular cell adhesion molecule 1	Homo sapiens	118-124
12372676-8	2002	Although zofenoprilat significantly and dose dependently reduced the expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), and E-selectin induced by ox-LDL (P <.01) and TNF-alpha (P <.01) on HUVECs, enalaprilat did not.	zofenoprilate	9-21	intercellular adhesion molecule 1	Homo sapiens	127-165
12372676-8	2002	Although zofenoprilat significantly and dose dependently reduced the expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), and E-selectin induced by ox-LDL (P <.01) and TNF-alpha (P <.01) on HUVECs, enalaprilat did not.	zofenoprilate	9-21	intercellular adhesion molecule 1	Homo sapiens	167-173
12372676-8	2002	Although zofenoprilat significantly and dose dependently reduced the expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), and E-selectin induced by ox-LDL (P <.01) and TNF-alpha (P <.01) on HUVECs, enalaprilat did not.	zofenoprilate	9-21	selectin E	Homo sapiens	180-190
12372676-8	2002	Although zofenoprilat significantly and dose dependently reduced the expression of vascular cell adhesion molecule-1 (VCAM-1), intercellular cell adhesion molecule-1 (ICAM-1), and E-selectin induced by ox-LDL (P <.01) and TNF-alpha (P <.01) on HUVECs, enalaprilat did not.	zofenoprilate	9-21	tumor necrosis factor	Homo sapiens	225-234
12372676-9	2002	Ox-LDL and TNF-alpha increased the activation of NF-kappaB and the preincubation of HUVECs with zofenoprilat, but not with enalaprilat, dose dependently reduced its activation (P <.001).	zofenoprilate	96-108	tumor necrosis factor	Homo sapiens	11-20
11145066-1	2000	Zofenopril is a pro-drug designed to undergo metabolic hydrolysis yielding the active free sulfhydryl compound zofenoprilat, which is an angiotensin converting enzyme (ACE) inhibitor, endowed also with a marked cardioprotective activity.	zofenoprilate	111-123	angiotensin I converting enzyme	Homo sapiens	168-171
2561143-6	1989	Furthermore, at comparable ACE-inhibiting doses, zofenoprilat was more effective in reducing mean arterial pressure, which might be related to the presence of a sulphydryl group.	zofenoprilate	49-61	angiotensin I converting enzyme	Rattus norvegicus	27-30
1475237-6	1992	Of all the compounds studied, the two most lipophilic ACE inhibitors, fosinoprilat and zofenoprilat, exhibit a rank-order correlation with respect to biliary excretion.	zofenoprilate	87-99	angiotensin I converting enzyme	Homo sapiens	54-57
1720843-1	1991	In this study, the effect of bradykinin on coronary flow in the isolated rat heart was significantly potentiated when cysteine or the sulfhydryl-containing converting enzyme inhibitors captopril and zofenoprilat were administered simultaneously.	zofenoprilate	199-211	kininogen 1	Homo sapiens	29-39
34916111-12	2022	Zofenoprilat inhibited the mitogen activated protein kinase and mammalian target of rapamycin pathways in SMCs and human vein segments.	zofenoprilate	0-12	mechanistic target of rapamycin kinase	Homo sapiens	64-93
20924096-4	2010	Intravenous injection of the active compounds of the 2 ACE inhibitors, zofenoprilat (288 nmol/kg) and ramiprilat (129 nmol/kg), caused similar hypotensive effects in anesthetized rabbits.	zofenoprilate	71-83	angiotensin-converting enzyme	Oryctolagus cuniculus	55-58
23868084-2	2013	We have studied the chain of events induced by angiotensin-converting-enzyme (ACE) activation in vascular umbilical vein endothelial cells (HUVECs) by using an ACE inhibitor such as zofenoprilat.	zofenoprilate	182-194	angiotensin I converting enzyme	Homo sapiens	47-76
23868084-2	2013	We have studied the chain of events induced by angiotensin-converting-enzyme (ACE) activation in vascular umbilical vein endothelial cells (HUVECs) by using an ACE inhibitor such as zofenoprilat.	zofenoprilate	182-194	angiotensin I converting enzyme	Homo sapiens	78-81
23868084-2	2013	We have studied the chain of events induced by angiotensin-converting-enzyme (ACE) activation in vascular umbilical vein endothelial cells (HUVECs) by using an ACE inhibitor such as zofenoprilat.	zofenoprilate	182-194	angiotensin I converting enzyme	Homo sapiens	160-163
23868084-4	2013	RESULTS: Zofenoprilat counteracts the superoxide anion production and cell apoptosis induced by angiotensin I treatment by blocking the extrinsic caspase cascade, NF-kB and p38 activation.	zofenoprilate	9-21	angiotensinogen	Homo sapiens	96-109
23868084-4	2013	RESULTS: Zofenoprilat counteracts the superoxide anion production and cell apoptosis induced by angiotensin I treatment by blocking the extrinsic caspase cascade, NF-kB and p38 activation.	zofenoprilate	9-21	mitogen-activated protein kinase 14	Homo sapiens	173-176
23868084-5	2013	p38 inhibitor SB203580 reverted the angiotensin II oxidant effects while the p38 constitutively activation, by MKK6 transfection, abrogated the zofenoprilat effects.	zofenoprilate	144-156	mitogen-activated protein kinase 14	Homo sapiens	77-80
23868084-5	2013	p38 inhibitor SB203580 reverted the angiotensin II oxidant effects while the p38 constitutively activation, by MKK6 transfection, abrogated the zofenoprilat effects.	zofenoprilate	144-156	mitogen-activated protein kinase kinase 6	Homo sapiens	111-115
23868084-6	2013	Characterizing the zofenoprilat downstream effector we found that zofenoprilat reverted the SirT-1 downregulation induced by angiotensin II.	zofenoprilate	19-31	sirtuin 1	Homo sapiens	92-98
23868084-6	2013	Characterizing the zofenoprilat downstream effector we found that zofenoprilat reverted the SirT-1 downregulation induced by angiotensin II.	zofenoprilate	19-31	angiotensinogen	Homo sapiens	125-139
23868084-6	2013	Characterizing the zofenoprilat downstream effector we found that zofenoprilat reverted the SirT-1 downregulation induced by angiotensin II.	zofenoprilate	66-78	sirtuin 1	Homo sapiens	92-98
23868084-6	2013	Characterizing the zofenoprilat downstream effector we found that zofenoprilat reverted the SirT-1 downregulation induced by angiotensin II.	zofenoprilate	66-78	angiotensinogen	Homo sapiens	125-139
23868084-9	2013	SirT1 inhibition by sirtinol annulled zofenoprilat action while SirT1 overexpression reverted the cytotoxic effects of angiotensin II.	zofenoprilate	38-50	sirtuin 1	Homo sapiens	0-5
23868084-10	2013	Finally, zofenoprilat negatively controlled angiotensin I receptor protein expression through SirT1.	zofenoprilate	9-21	angiotensinogen	Homo sapiens	44-57
23868084-10	2013	Finally, zofenoprilat negatively controlled angiotensin I receptor protein expression through SirT1.	zofenoprilate	9-21	sirtuin 1	Homo sapiens	94-99
27650753-3	2016	We have recently demonstrated that the SH containing ACE inhibitor zofenoprilat, the active metabolite of zofenopril, controls the angiogenic features of vascular endothelium through H2S enzymatic production by cystathionine gamma lyase (CSE).	zofenoprilate	67-79	angiotensin I converting enzyme	Homo sapiens	53-56
27650753-5	2016	Here we found that zofenoprilat, in a CSE/H2S-mediated manner, abolished all the inflammatory features induced by interlukin-1beta (IL-1beta) in human umbilical vein endothelial cells (HUVEC), especially the NF-kappaB/cyclooxygenase-2 (COX-2)/prostanoid biochemical pathway.	zofenoprilate	19-31	interleukin 1 beta	Homo sapiens	132-140
27650753-6	2016	The pre-incubation with zofenoprilat/CSE dependent H2S prevented IL-1beta induced paracellular hyperpermeability through the control of expression and localization of cell-cell junctional markers ZO-1 and VE-cadherin.	zofenoprilate	24-36	interleukin 1 beta	Homo sapiens	65-73
27650753-6	2016	The pre-incubation with zofenoprilat/CSE dependent H2S prevented IL-1beta induced paracellular hyperpermeability through the control of expression and localization of cell-cell junctional markers ZO-1 and VE-cadherin.	zofenoprilate	24-36	cadherin 5	Homo sapiens	205-216
27650753-7	2016	Moreover, zofenoprilat/CSE dependent H2S reduced the expression of the endothelial markers CD40 and CD31, involved in the recruitment of circulating mononuclear cells and platelets.	zofenoprilate	10-22	CD40 molecule	Homo sapiens	91-95
27650753-7	2016	Moreover, zofenoprilat/CSE dependent H2S reduced the expression of the endothelial markers CD40 and CD31, involved in the recruitment of circulating mononuclear cells and platelets.	zofenoprilate	10-22	platelet and endothelial cell adhesion molecule 1	Homo sapiens	100-104
27650753-8	2016	Interestingly, this anti-inflammatory activity was also confirmed in vascular smooth muscle cells and fibroblasts as zofenoprilat reduced, in both cell lines, proliferation, migration and COX-2 expression induced by IL-1beta, but independently from the SH moiety and H2S availability.	zofenoprilate	117-129	interleukin 1 beta	Homo sapiens	216-224
25631232-7	2015	The molecular mechanisms underlying H2 S/zofenoprilat-induced angiogenesis were dependent on Akt, eNOS and ERK1/2 cascades.	zofenoprilate	41-53	AKT serine/threonine kinase 1	Homo sapiens	93-96
25631232-7	2015	The molecular mechanisms underlying H2 S/zofenoprilat-induced angiogenesis were dependent on Akt, eNOS and ERK1/2 cascades.	zofenoprilate	41-53	nitric oxide synthase 3	Homo sapiens	98-102
25631232-7	2015	The molecular mechanisms underlying H2 S/zofenoprilat-induced angiogenesis were dependent on Akt, eNOS and ERK1/2 cascades.	zofenoprilate	41-53	mitogen-activated protein kinase 3	Homo sapiens	107-113
25631232-10	2015	CONCLUSIONS AND IMPLICATIONS: Zofenoprilat induced a constant production of H2 S that stimulated the angiogenic process through a KATP channel/Akt/eNOS/ERK1/2 pathway.	zofenoprilate	30-42	AKT serine/threonine kinase 1	Homo sapiens	143-146
25631232-10	2015	CONCLUSIONS AND IMPLICATIONS: Zofenoprilat induced a constant production of H2 S that stimulated the angiogenic process through a KATP channel/Akt/eNOS/ERK1/2 pathway.	zofenoprilate	30-42	nitric oxide synthase 3	Homo sapiens	147-151
25631232-10	2015	CONCLUSIONS AND IMPLICATIONS: Zofenoprilat induced a constant production of H2 S that stimulated the angiogenic process through a KATP channel/Akt/eNOS/ERK1/2 pathway.	zofenoprilate	30-42	mitogen-activated protein kinase 3	Homo sapiens	152-158
23965518-0	2013	The sulphydryl containing ACE inhibitor Zofenoprilat protects coronary endothelium from Doxorubicin-induced apoptosis.	zofenoprilate	40-52	angiotensin I converting enzyme	Homo sapiens	26-29
23965518-6	2013	P53 mediated-apoptosis and impairment of survival were reverted by treatment with Zofenoprilat.	zofenoprilate	82-94	tumor protein p53	Homo sapiens	0-3
15998238-1	2005	The ability of Zofenoprilat, an angiotensin-converting enzyme inhibitor carrying a thiol group, to intervene in protein S-thiolation processes was tested on bovine lens aldose reductase (ALR2).	zofenoprilate	15-27	aldose reductase	Bos taurus	169-185
19079593-4	2008	However, zofenoprilat (-42% after 8 hours of incubation) was more effective (P < .05) than enalaprilat (-25%), lisinopril (-21%), and captopril (-30%) in reducing endothelin-1 secretion.	zofenoprilate	9-21	endothelin 1	Homo sapiens	166-178
19079593-8	2008	In conclusion, among the four tested ACE-I, zofenoprilat was more effective in improving endothelin-1/nitric oxide balance in HUVECs likely because of its greater antioxidant properties.	zofenoprilate	44-56	endothelin 1	Homo sapiens	89-101
16868034-8	2006	The overexpression of eNOS/FGF-2 produced, at the functional level, enhanced cell proliferation and migration, the latter effect being dose-dependent and maximal at 0.1 microM zofenoprilat.	zofenoprilate	176-188	nitric oxide synthase 3	Homo sapiens	22-26
16868034-8	2006	The overexpression of eNOS/FGF-2 produced, at the functional level, enhanced cell proliferation and migration, the latter effect being dose-dependent and maximal at 0.1 microM zofenoprilat.	zofenoprilate	176-188	fibroblast growth factor 2	Homo sapiens	27-32
16868034-11	2006	At the endothelial membrane level, zofenoprilat appeared to activate the bradykinin B1 receptor, a known stimulant of FGF-2 expression.	zofenoprilate	35-47	bradykinin receptor B1	Homo sapiens	73-95
16868034-11	2006	At the endothelial membrane level, zofenoprilat appeared to activate the bradykinin B1 receptor, a known stimulant of FGF-2 expression.	zofenoprilate	35-47	fibroblast growth factor 2	Homo sapiens	118-123
16452552-7	2006	The presence of either of the ACE inhibitors counteracted several of the deleterious effects of high glucose exposure, including reduction of insulin secretion and increased oxidative stress; zofenoprilat showed significantly more marked effects.	zofenoprilate	192-204	angiotensin I converting enzyme	Homo sapiens	30-33
16452552-8	2006	CONCLUSIONS: These results showed that: (a) RAS molecules are present in human islets and their expression is sensitive to glucose concentration, (b) ACE inhibitors, and in particular zofenoprilat, protect human islets from glucotoxicity and (c) the effects of ACE inhibition are associated with decreased oxidative stress.	zofenoprilate	184-196	angiotensin I converting enzyme	Homo sapiens	261-264
15998238-5	2005	Indeed, the S-thiolation of ALR2 by ZSSG occurred exclusively through the insertion of the Zofenoprilat moiety of ZSSG on the enzyme.	zofenoprilate	91-103	lens aldose reductase pseudogene	Bos taurus	28-32
15998238-1	2005	The ability of Zofenoprilat, an angiotensin-converting enzyme inhibitor carrying a thiol group, to intervene in protein S-thiolation processes was tested on bovine lens aldose reductase (ALR2).	zofenoprilate	15-27	lens aldose reductase pseudogene	Bos taurus	187-191